Quick Update for Sarepta Therapeutics (SRPT) Investors

By Naomi Wentworth • Tuesday, September 26 09:41 • Permanent Link

We're taking a closer look at Sarepta Therapeutics today, as the chatter surrounding the stock has increased notably in the last few weeks. Today, its shares moved 2.0% compared to -1.0% for the S&P 500. Increased investor interest and volatility surrounding the stock are not reason enough to buy in -- you should first perform your own due diligence. Here are some figures that can get you started:

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases.
Sarepta Therapeutics has moved 8.0% over the last year compared to 19.0% for the S&P 500 -- a difference of -11.0%
SRPT has an average analyst rating of buy and is -35.33% away from its mean target price of $180.94 per share
Its trailing 12 month earnings per share (EPS) is $-10.33
Sarepta Therapeutics has a trailing 12 month Price to Earnings (P/E) ratio of -11.3 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $3.76 and its forward P/E ratio is 31.1
SRPT has a Price to Earnings Growth (PEG) ratio of -0.15, which shows the company is fairly valued compared to its earnings.
The company has a Price to Book (P/B) ratio of 14.72 in contrast to the S&P 500's average ratio of 2.95
Sarepta Therapeutics is part of the Health Care sector, which has an average P/E ratio of 24.45 and an average P/B of 4.16
Sarepta Therapeutics has on average reported free cash flows of $-296620166.7 over the last four years, during which time they have grown by an an average of -0.0%

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.